Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Sorry, I got timed out before I could

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Lima4918 Member Profile
 
Followed By 9
Posts 852
Boards Moderated 1
Alias Born 06/14/18
160x600 placeholder
Anavex Life Sciences Provides Update on Clinical Program Development as Response to COVID-19 GlobeNewswire Inc. - 3/31/2020 7:00:10 AM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 3/23/2020 8:01:22 AM
Anavex Life Sciences to Webcast 2020 Annual Meeting of Shareholders GlobeNewswire Inc. - 3/23/2020 8:00:10 AM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 3/9/2020 4:28:38 PM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Multiple Sclerosis (MS) GlobeNewswire Inc. - 2/24/2020 7:00:10 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 2/20/2020 4:32:14 PM
Amended Statement of Ownership (sc 13g/a) Edgar (US Regulatory) - 2/14/2020 4:38:56 PM
PURA ALERT - MACD Cross Pushing $0.039 50 Day MA With $0.35 Analyst TGT Recommendation InvestorsHub NewsWire - 2/10/2020 12:50:46 PM
PURA BUY Recommendation at $0.03 Issued By AmericanBulls InvestorsHub NewsWire - 2/7/2020 10:33:33 AM
Anavex Life Sciences Reports Fiscal 2020 First Quarter Financial Results and Provides Clinical Study Updates GlobeNewswire Inc. - 2/6/2020 7:00:10 AM
Anavex Life Sciences to Present and Participate in a Panel at the 2020 BIO CEO & Investor Conference GlobeNewswire Inc. - 2/4/2020 7:00:10 AM
Anavex Life Sciences Announces Fast Track Designation Granted by U.S. FDA for ANAVEX®2-73 (blarcamesine) Clinical Developmen... GlobeNewswire Inc. - 2/3/2020 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2020 First Quarter Financial Results on Thursday, February 6th, 2020 GlobeNewswire Inc. - 1/30/2020 7:00:10 AM
Anavex Life Sciences Announces Achievement of Enrollment Target for the ANAVEX®2-73 (blarcamesine) Phase 2 Parkinson’s Dis... GlobeNewswire Inc. - 1/27/2020 7:00:10 AM
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 6:00:00 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Lima4918   Saturday, 06/01/19 08:16:55 PM
Re: Lima4918 post# 195124
Post # of 244054 
Sorry, I got timed out before I could finish editing. This is the intended post. Sorry.

Quote:
Obviously, this kind of Consortium would not happen w/o the SAUCE and the common belief held by a lot of smart people that they will make this work.



Do they really know we have the secret sauce? I know some people on this board do not like to speculate, but here it is anyways...

Anavex began using Cognision in November 2014, to measure and analyze cognitive biomarkers in 32 Alzheimers patients in a Ph2a 273 study in Australia.

In October 2018 Anavex presents 148 week data on these patients at CTAD. Harold Hampel is quoted as saying "we are about to start with a new study, a phase 2b/3 study, this year - it has already been approved"

In December 2018 Cecchi at Cognision files a patent as inventor of a dosage scheme for Anavex 273 (on and off dosing schedule).

Let's stop here. How much data has Cognision seen through the filing of this patent? How much real time data has Anavex and Cognision seen through December 2018? This is NOT a controlled, blinded trial.

In March 2019 the Schizophrenia Consortium is formed with 3 Huge Pharma companies, Anavex, and Cognision. Let's leave out the other small players because that's just noise to distract you.

How much data is available to Anavex and Cognision through March 2019, which is when this good old boys exclusive club was formed?

Also in March 2019, Kaufman presents the same 148 week data that Hampel presented at CTAD 2018, but more than 5 months later.

How much data is available to our CMO on March 29th when he struts to the stage and presents "stale" 148 week data? I mean what's the point of that unless you had ALL of the data available to see through March 29th, that's more than 4 years of data even though you are only presenting 148 weeks of data. If I am Kaufman, and the data past 148 weeks sucks, I am not presenting Sh%&.

You see, the Secret Sauce is predicated on having really good data.

Speaking of good data, In April 2019 Anavex files a patent relating to the therapeutic benefit of 273 in cardiac dysfunction. Where is this data coming from? Missling has been colecting data with Cognision for more than 4 years, why? Because that's what Missling does. Our drug has an impact on many ailments, and cardiac dysfunction is one of those ailments.

The Aussies are benefiting from Anavex 273 well past 148 weeks, and that can be clearly seen in the timeline of events involving Anavex, Cognision, the Consortium, and Walter Kaufman's actions.

The thing is that Cognision is allowing us to see data as it is processed, and the data is so damn good that Consortiums are being formed, world renowned Rett expert Walter Kaufman is leading the parade on stage, Frugal Missling ordering $1M commercial supply of 273, and now Missling is leading workshops and co-paneling close out sessions at a Psychiatric Drug Development Summit that is being spearheaded by Lundbeck, Sage, and Johnson and Johnson?

Ananvex and Cognision go back more than 4 years and NOW is when others want "in" on this precision medicine thing?

Focus on the timeline of events AND the availability of internal readouts by the company and Cognision. It does not take a rocket scientist to figure out that this data changes the GAME.

The peer reviewed paper on the 148 week data is the death blow.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (1) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist